MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis March 6, 2020checkorphan Learn more about: Zellweger syndrome Related Clinical Trial MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis Hydroxychloroquine Administration for Reduction of Pexophagy Study of Bile Acids in Patients With Peroxisomal Disorders Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid Recruitment InformationAdministrative Informations